Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Market Closed 07-24 16:00:00 EDT

1.61

-0.05

-3.01%

盘后1.61

+0.00+0.02%

19:58 EDT

High1.68	Low1.61	Vol33.44K
Open1.66	D1 Closing1.66	Amplitude4.22%
Mkt Cap2.39M	Tradable Cap2.39M	Total Shares1.49M
T/O54.80K	T/O Rate2.25%	Tradable Shares1.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":1.61,"timestamp":1784923200000,"preClose":1.66,"halted":0,"volume":33440,"hourTrading":{"tag":"盘后","latestPrice":1.6103,"preClose":1.61,"latestTime":"19:58 EDT","volume":730,"amount":1185.6542,"timestamp":1784937525580,"change":0.0003,"changeRate":0.000186,"amplitude":0.024845},"delay":0,"changeRate":-0.03012048192771074,"floatShares":1484199,"shares":1485551,"eps":-175.92,"marketStatus":"Market Closed","change":-0.05,"latestTime":"07-24 16:00:00 EDT","open":1.66,"high":1.68,"low":1.61,"amount":54797.435792,"amplitude":0.042169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-175.92,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":1.66,"preHourTrading":{"tag":"盘前","latestPrice":1.65,"preClose":1.66,"latestTime":"09:24 EDT","volume":405,"amount":668.67039,"timestamp":1784899499880,"change":-0.01,"changeRate":-0.006024,"amplitude":0.006024},"postHourTrading":{"tag":"盘后","latestPrice":1.6103,"preClose":1.61,"latestTime":"19:58 EDT","volume":730,"amount":1185.6542,"timestamp":1784937525580,"change":0.0003,"changeRate":0.000186,"amplitude":0.024845},"volumeRatio":0.21478700004528248},"requestUrl":"/m/hq/s/CMND","defaultTab":"news","newsList":[{"id":"2652218436","title":"Clearmind Targets Hong Kong Patent Protection to Support PTSD Drug Development Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218436?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:55","pubTimestamp":1784548528,"startTime":"0","endTime":"0","summary":"Clearmind targets Hong Kong patent protection to support PTSD drug development pushClearmind set plans to expand patent protection in Asia via a Hong Kong filing for novel psychedelic compounds aimed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL8RgMRm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","IE00BGHQF748.EUR","CMND","BCDF","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014005.SGD","BK4007","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","LU0314104364.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652184812","title":"Clearmind Medicine - Files Hong Kong Patent Application for Psychedelic Compounds Targeting Ptsd","url":"https://stock-news.laohu8.com/highlight/detail?id=2652184812","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652184812?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:55","pubTimestamp":1784548511,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M0MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651447129","title":"Clearmind reports positive retention results for intranasal formulation of MEAI","url":"https://stock-news.laohu8.com/highlight/detail?id=2651447129","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651447129?lang=en_us&edition=fundamental","pubTime":"2026-07-16 21:35","pubTimestamp":1784208957,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced “compelling” ex vivo mucoadhesion results for its intranasal formulation of MEAI. “Leveraging a nasal drug-deli...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-reports-positive-retention-results-for-intranasal-formulation-of-meai-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-reports-positive-retention-results-for-intranasal-formulation-of-meai-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651573447","title":"Clearmind Medicine Releases Update on Intranasal MEAI Formulation Retention Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2651573447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651573447?lang=en_us&edition=fundamental","pubTime":"2026-07-16 21:30","pubTimestamp":1784208616,"startTime":"0","endTime":"0","summary":"Clearmind Medicine releases update on intranasal MEAI formulation retention studyClearmind Medicine reported positive ex vivo mucoadhesion results for an intranasal MEAI formulation, showing higher na","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL843lz6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","CMND","BK4588","SG9999014021.USD","IE00BN0W2T93.GBP","BCDF","LU2210149790.SGD","IE00BGHQF748.EUR","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","IE00B64PRP62.GBP","NDAQ","SG9999014013.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4007","IE00BN0W2V16.EUR","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651644752","title":"Clearmind Medicine - Results Validate Clearmind Nasal Drug-delivery Platform for Meai","url":"https://stock-news.laohu8.com/highlight/detail?id=2651644752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651644752?lang=en_us&edition=fundamental","pubTime":"2026-07-16 21:30","pubTimestamp":1784208608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nFWN43I14D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651447547","title":"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of Its Psychedelic-based Neuroplastogen Meai","url":"https://stock-news.laohu8.com/highlight/detail?id=2651447547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651447547?lang=en_us&edition=fundamental","pubTime":"2026-07-16 21:30","pubTimestamp":1784208608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nFWN43I14D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651898111","title":"Clearmind Medicine Posts Update on Cmnd-100 First-in-human Trial Webinar Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=2651898111","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651898111?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:18","pubTimestamp":1783945086,"startTime":"0","endTime":"0","summary":"Clearmind Medicine posts update on CMND-100 first-in-human trial webinar insightsClearmind Medicine published an update on early real-world insights from its ongoing first-in-human Phase I/IIa CMND-10","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL22dlTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00B3QW5Z07.USD","BK4585","SG9999014013.SGD","LU2095319765.USD","IE00BKPKM429.USD","CMND","LU2210149790.SGD","BCDF","IE00BN0W2T93.GBP","LU0314104364.USD","BK4112","LU2210150020.SGD","IE00BGHQF748.EUR","NDAQ","SG9999014039.USD","BK4007","BK4588","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650405180","title":"Clearmind Medicine submits response to HHS request for information","url":"https://stock-news.laohu8.com/highlight/detail?id=2650405180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650405180?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:41","pubTimestamp":1783687298,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced that it has submitted a formal response to the U.S. Department of Health and Human Services, or HHS, request fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-response-to-hhs-request-for-information-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-response-to-hhs-request-for-information-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HHS","BK4007","BK4009","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650996180","title":"Clearmind Medicine Responds to the U.S. Administration’s Rfi for Addiction Treatment Innovations as Part of the Great American Recovery Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2650996180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650996180?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:32","pubTimestamp":1783686726,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C0FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649937994","title":"Clearmind Reports Successful Formulation Study for Intranasal MEAI Delivery in Alcohol Use Disorder Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2649937994","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649937994?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:02","pubTimestamp":1783454549,"startTime":"0","endTime":"0","summary":"Clearmind reports successful formulation study for intranasal MEAI delivery in alcohol use disorder programClearmind disclosed successful formulation-feasibility results for intranasal delivery of its","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL8TsSw8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649498252","title":"Clearmind Medicine Issues Press Release Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2649498252","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649498252?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:42","pubTimestamp":1783424544,"startTime":"0","endTime":"0","summary":"Clearmind Medicine issues press release updateClearmind published a press release on July 7, 2026, reporting a successful formulation feasibility study for intranasal delivery of MEAI.Results showed M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL2KQmBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4588","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","CMND","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","NDAQ","BK4585","BK4112","SG9999014005.SGD","LU2210150020.SGD","BCDF","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4007","LU2095319765.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647795853","title":"Clearmind Medicine Wins New US Patent for Binge Behavior Regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=2647795853","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647795853?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:55","pubTimestamp":1782734113,"startTime":"0","endTime":"0","summary":"Clearmind Medicine wins new US patent for binge behavior regulatorsClearmind Medicine received a newly granted U.S. patent for “Binge Behavior Regulators,” U.S. Patent No. 12,357,590.The patent expand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL6Lkzx3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","CMND","LU2210150020.SGD","NDAQ","LU2095319765.USD","SG9999014005.SGD","BK4588","SG9999014013.SGD","IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU0314104364.USD","BK4007","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645602442","title":"Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645602442","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645602442?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:07","pubTimestamp":1782130036,"startTime":"0","endTime":"0","summary":"Clearmind Medicine completed Part A treatment in its FDA-regulated Phase I/II trial of CMND-100 for Alcohol Use Disorder.Results have not been presented; the dataset is under review.All 24 participants across four cohorts finished dosing under the study protocol.Next-stage initiation is planned if the review remains favorable, marking a potential advance in its AUD development program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL9kp5TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","LU2210149790.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BGHQF748.EUR","CMND","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645102441","title":"Clearmind Medicine - to Initiate Next Stage of Clinical Program for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645102441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645102441?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:07","pubTimestamp":1782130020,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2FQJGV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024465","title":"Clearmind Medicine Reaches Major Milestone, Completing Part a Treatment in FDA‑Regulated Phase I/Ii Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024465?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:07","pubTimestamp":1782130020,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2FQJGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644397420","title":"HRT Financial LP disposes of $73,191 in Clearmind Medicine common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644397420","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644397420?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:06","pubTimestamp":1781816779,"startTime":"0","endTime":"0","summary":"HRT Financial LP cut its stake in Clearmind Medicine, selling 22,139 Class A shares on June 16.The shares were sold at USD 3.31 each.HRT Financial LP reported 81,353 Class A shares beneficially owned following the sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1yFnJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HRT Financial LP disposes of $73,191 in Clearmind Medicine common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644330081","title":"Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644330081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644330081?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:00","pubTimestamp":1781791242,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing completion, psilocybin p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-part-a-dosing-for-phase-i-ii-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-part-a-dosing-for-phase-i-ii-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644088020","title":"Clearmind Medicine wins US patent for MEAI-based binge behavior regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=2644088020","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644088020?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:55","pubTimestamp":1781783717,"startTime":"0","endTime":"0","summary":"Clearmind Medicine won a U.S. patent covering compositions and methods using MEAI salts to regulate binge behaviors.The USPTO issued Patent No. 12,350,242, titled “Binge Behavior Regulators.”Scope includes potential use in binge-related disorders, including alcohol use disorder.Clearmind said the grant lifts its portfolio to 32 issued patents.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLcbfqj7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","SG9999014039.USD","SG9999014005.SGD","BK4007","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BN0W2V16.EUR","BK4585","CMND","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","NDAQ","BK4588","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644721750","title":"HRT Financial LP sells 3,183 Clearmind Medicine common shares for $10,567.56","url":"https://stock-news.laohu8.com/highlight/detail?id=2644721750","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644721750?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:43","pubTimestamp":1781729014,"startTime":"0","endTime":"0","summary":"HRT Financial, a 10% owner of Clearmind Medicine, sold 3,183 common shares on June 15, 2026 at $3.32.Stake fell to 103,492 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6qYvPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HRT Financial LP sells 3,183 Clearmind Medicine common shares for $10,567.56","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643750188","title":"HRT Financial LP disposes of 2,102 Clearmind Medicine common shares worth $7,062.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2643750188","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643750188?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:19","pubTimestamp":1781615996,"startTime":"0","endTime":"0","summary":"HRT Financial, a 10% owner of Clearmind Medicine, sold 2,102 common shares on June 12, 2026 at USD 3.36.Stake fell to 106,675 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL7SgdYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HRT Financial LP disposes of 2,102 Clearmind Medicine common shares worth $7,062.72","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.1701},{"period":"1month","weight":-0.3993},{"period":"3month","weight":-0.8017},{"period":"6month","weight":-0.9412},{"period":"1year","weight":-0.9961},{"period":"ytd","weight":-0.911}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.280646},{"month":4,"riseRate":0.25,"avgChangeRate":-0.205941},{"month":5,"riseRate":0.25,"avgChangeRate":-0.137133},{"month":6,"riseRate":0.25,"avgChangeRate":-0.036058},{"month":7,"riseRate":0.25,"avgChangeRate":-0.060665},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction